Aditxt appoints Evofem CEO Saundra Pelletier to board; officer loans $70K

Aditxt, Inc.

Board appoints Saundra Pelletier (CEO of Evofem) as director, effective June 5, 2025.
Chief Innovation Officer Shahrokh Shabahang loans $70,000 at 7.5%, due Dec 5, 2025.
Weekly update: Adimune targets Q4 2025 regulatory submission for ADI-100 autoimmune therapy.
Evofem generated $20M net revenue in 2024; CEO cites capital dependency for growth.
Pending Evofem merger extended to Sept 30, 2025; capital needed for milestones.

item 1.01 item 2.03 item 3.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Saundra Pelletier

director

ADTX · Aditxt, Inc.

Effective: 2025-06-05
Filed: June 9, 2025, 7:59 PM ET

On June 5, 2025, the Board of Directors (the “ Board ”) of the Company, with the recommendation of the Nominating and Corporate Governance Committee, appointed Ms. Saundra Pelletier as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Saundra Pelletier was appointed as director at Aditxt, Inc..

Action: appointed
Role: director

Exact text from the filing

On June 5, 2025, the Board of Directors (the “ Board ”) of the Company, with the recommendation of the Nominating and Corporate Governance Committee, appointed Ms. Saundra Pelletier as a member of the Board.

View on SEC.gov

Aditxt, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-052635

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.